Related Experiment Videos
Treatment of childhood meningitis with mezlocillin
Abstract:
30 children suffering from bacterial meningitis and 2 children suffering from septicemia were treated with 6-((R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetmido(-penicillanic acid sodium salt (mezlocillin, Baypen). The daily dose was 250 mg/kg, divided in three portions. Therapy was successful in all patients. Neither signs of toxicity nor side effects of any kind could be found. Mezlocillin concentrations were measured in serum and cerebrospinal fluid (CSF) mainly on days one and six or seven of therapy. Serum concentrations were in the expected range. CSF concentrations depended on the inflammation of the meninges. On the first day of treatment they ranged from 0.5 to 7.2 to 12.0 microgram/ml. After normalisation of CSF no concentrations of mezlocillin were detectable.
Insights
Mezlocillin effectively treated bacterial meningitis and septicemia in children with no observed side effects. Drug levels in serum and cerebrospinal fluid were therapeutic, indicating successful treatment.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Bacterial meningitis and septicemia are severe infections in children.
- Effective antibiotic therapy is crucial for favorable outcomes.
- Mezlocillin is a penicillin-class antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of mezlocillin in treating pediatric bacterial meningitis and septicemia.
- To determine mezlocillin serum and cerebrospinal fluid (CSF) concentrations during treatment.
Main Methods:
- A cohort of 32 children (30 with bacterial meningitis, 2 with septicemia) received mezlocillin.
- The daily dose was 250 mg/kg, administered in three divided doses.
- Serum and CSF drug concentrations were measured on days 1 and 6-7 of therapy.
Main Results:
- Therapy with mezlocillin was successful in all pediatric patients.
- No signs of toxicity or adverse side effects were reported.
- Serum mezlocillin concentrations were within expected ranges.
- CSF concentrations varied with meningeal inflammation, ranging from 0.5 to 12.0 microgram/ml on day 1.
- Mezlocillin was undetectable in CSF after normalization.
Conclusions:
- Mezlocillin demonstrates high efficacy and an excellent safety profile for treating bacterial meningitis and septicemia in children.
- Achieved therapeutic drug concentrations in serum and CSF support its clinical effectiveness.
- Further investigation into optimal dosing and specific pathogens may be warranted.